Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03245580 · ClinicalTrials.gov registry record · NA
Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)
A NA study of Liver Diseases, sponsored by Parkview Health.
- Completed
- Registry status
- NA
- Development phase
- 153
- Enrollment target
- 7
- Study locations
NCT03245580: Completed NA study of Liver Diseases, sponsored by Parkview Health.
NCT03245580 is a NA study of Liver Diseases that has completed, run by Parkview Health. The registered enrollment target is 153 participants, below the 61,154-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03245580, a NA study of Liver Diseases, has completed, sponsored by Parkview Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 153 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this prospective, randomized, multicenter study is to evaluate and compare the amount and quality of tissue samples yielded in a liver biopsy comparing 2 different techniques of EUS guided CORE liver biopsy for benign disease. The two techniques: "modified Wet suction" and "Slow pull" technique of collecting tissue from a liver biopsy via Endoscopic Ultrasound (EUS).
Primary Outcome
To determine if there is a significant difference in pathological yield as determined by fragmentation of portal tracts of the biopsy sample between a "modified wet suction," and "slow pull" techniques in obtaining CORE of histologic tissue. Pathological yield will be measured by assessment of portal tracts fragmentation by designated pathologists with experience in liver biopsy specimens.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Core Liver Biopsy
Study Locations (7)
Indiana
- Parkview Regional Medical Center - Fort Wayne
- Indiana University - Indianapolis
Alabama
- University South Alabama - Mobile
California
- Santa CLara Valley Medical Center - San Jose
Louisiana
- Oschner Health System - New Orleans
Pennsylvania
- Geisinger Medical Center - Danville
Texas
- Baylor Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2018-03-08 |
| Est. Completion | 2020-09-15 |
| Phase | NA |
What the finished NCT03245580 record still lists
NCT03245580 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 61,154-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Liver Diseases appearing as the primary indexed condition, and to 1 intervention - of which Core Liver Biopsy is the first listed.
NCT03245580 lists 7 locations in 6 states (Indiana, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT03245580 about?
NCT03245580 is a clinical study titled "Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)". The primary purpose of this prospective, randomized, multicenter study is to evaluate and compare the amount and quality of tissue samples yielded in a liver biopsy comparing 2 different techniques of EUS guided CORE liver biopsy for benign disease. The two techniques: "modified Wet suction" and "Sl...
What is the current status of trial NCT03245580?
This trial is currently completed. It is a NA study. The enrollment target is 153 participants. The study started on 2018-03-08. Estimated completion is 2020-09-15.
What conditions does trial NCT03245580 study?
This clinical trial studies the following conditions: Liver Diseases.
What interventions are being tested in trial NCT03245580?
The interventions under investigation include: Core Liver Biopsy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03245580?
This trial is sponsored by Parkview Health, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03245580 being conducted?
This trial has 7 study locations across Alabama, California, Indiana, Louisiana, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03245580's enrollment target sits among peer trials
153 17th of 33 higher than 17 of 33 other Liver Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
RECRUITING · NA
-
A Trial of Post-Discharge Transitional Care for Patients With Chronic Liver Disease
RECRUITING · NA
-
Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement
RECRUITING · NA
-
Liver Cancer Prevention Randomized Control Trial
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI